Tetra Bio-Pharma’s Management Provides Corporate Update Ahead of Annual General Meeting
Momentum Public Relations
Press Release: June 18, 2019
- U.S. granted patent protection for ophthalmic use;
- U.S. granted patent protection for topical delivery, increased drug solubility and abuse deterrence;
- U.S. FDA provides positive response on painful dry eye development program;
- Panag completes a Phase 3 clinical trial for a topical pain reliever;
- Tetra completes four clinical trials;
- Serenityã trial to launch in USA and Canada; and
- Promised revenues to meet delivery targets.
OTTAWA, June 18, 2019 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V: TBP) (OTCQB: TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, is pleased to provide investors with an update on our research, regulatory and commercial activities. This market update covers Tetra and its subsidiaries, Panag and Tetra Natural Health (TNH).
Tetra has grown from a small biotech to a biopharma with an enviable drug pipeline covering ophthalmic, chronic pain and oncology. The Company has completed four clinical trials providing in-depth knowledge on the safety and pharmacokinetics (how drugs are absorbed in the body) as well as preliminary data on the efficacy of several THC-CBD combinations. The Corporation acquired a large base of patent protection through its acquisition of Panag Pharma, and by forming partnerships with Altus Formulations (Altus) and Crescita Therapeutics (Crescita).
“Tetra’s pipeline is focused on large markets that represent significant potential revenues,” said Dr. Guy Chamberland, CEO and CSO of Tetra. “Our focus on these large markets has not precluded us from actively seeking Orphan Drug Designations. Delivering on our research promises along with solid patent protection has seen our story resonate with U.S. based institutional investors.”
Patent Equity Developments
The Corporation acquired Panag for its expertise in drug development as well as its drug pipeline and intellectual property. “This acquisition is very exciting for Tetra because it positions the Corporation as a key player in the ophthalmic inflammation and pain markets with Panag’s U.S. granted patent (U.S. patent no. 9,765,386 issued on January 24, 2017 for Compositions and Methods for Treatment of Ocular Inflammation and/or Pain),” commented Dr. Chamberland. “Our Joint Venture with Altus brings us multiple U.S. granted patents that cover insoluble drug delivery as well as drug abuse deterrence. A strong regulatory strategy along with Panag’s and Altus’ patents provides Tetra with a solid base of protection to bring these innovative drugs to market.”
Revenues
The Corporation promised revenues at the last Annual General Meeting of shareholders and has delivered on its promise with the Hemp Energy Drink. We will update shareholders on this at the upcoming AGM. “Further, with the acquisition of Panag this revenue stream is expected to grow before the end of fiscal 2019 and should exceed the previously promised target,” said Dr. Chamberland. The Corporation entered into a Joint Venture with Crescita to leverage the Panag topical technology which Tetra intends on launching multiple products within the natural health market by the end of this fiscal year. Similarly, the Corporation will submit several over the counter (i.e., DIN) drug applications by the end of this fiscal year. Crescita is also supported with a granted patent protection (U.S. patent number 8,343,962). Dr. Chamberland further commented, “The topical product launches will become an important revenue stream as Tetra moves full speed ahead with its drug development activities.”
Last week Panag announced the completion of the randomized controlled Phase 3 trial (PANAG – 001) and Tetra is in commercial discussions to expand sales of AwayeÔ in Europe. Data from the Phase 3 trial will allow Tetra to support all dermatology product candidates with strong evidence for efficacy claims. Tetra will use Crescitas’ MMPE™ patented delivery technology to improve the permeability of the active ingredient and develop the next generation of topical products. The patented Crescita formulation technology is part of the strategy to create prescription or OTC drug products for patient care.
Tetra Bio-Pharma Clinical Trial Updates:
Caumz:
Tetra has been ramping up activities to complete the CAUMZ™ Phase 3 clinical trial, called SERENITY©. The primary endpoint is to improve Health Related Quality of Life (HrQOL) in advanced cancer patients suffering from pain. Tetra has already secured more than 20 clinical sites, with 10 based in the United States. Tetra continues to plan for marketing approval by late 2020. We expect to submit regulatory approval documents beginning in Q4 of 2019. CAUMZ™ is a cannabinoid-derived medicine using synthetic THC and CBD which will be delivered using a vaporizer called the Mighty Medic, an approved Class 2 Health Canada medical device. Tetra is already involved in several discussions with potential commercialization partners from around the world.
Tetra is also preparing to resume activities associated with its Phase 2 trial called REBORN© which is a Head to Head Efficacy Study assessing CAUMZ™ versus Fentanyl® to study the onset of action for breakthrough pain in cancer patients. Tetra has been relocating these clinical activities to the USA with the objective to secure a second indication for CAUMZ™ in breakthrough cancer pain by mid-2021. This will significantly increase CAUMZ™ sales in year two.
Tetra will also launch a Phase 2 trial in fibromyalgia in 2020 for its product candidate CAUMZ™ in neuropathic pain as it expands the medical indications for use in its marketing claims. If approved by regulatory agencies, this would significantly impact sales by tapping into large therapeutic areas with unmet needs.
“We have successfully approached large, highly reputed clinical sites in the USA, a development that will bring two major advantages to Tetra: global credibility for our trials and increased speed of enrollment,” commented Dr. Chamberland.
PPP002:
As reported in Autumn 2018, the U.S. FDA, during both a Type B and Type C meetings, gave the greenlight to Tetra’s New Drug Application (NDA) under 505(b)(2). Tetra intends to file a New Drug Application (NDA) to bring PPP002 Dronabinol AdVersa™ to market. The PPP002 product is based on IntelGenX’s proprietary delivery system which should significantly reduce side effects and improve symptoms for patients suffering from Chemotherapy Induced Nausea and Vomiting (CINV).
In Q4 of this year, Tetra will launch the OPIOSPARE© clinical trial that will document opioid usage when patients take PPP002. Tetra will then seek to expand the marketing claims associated with PPP002 in order to increase the patient pool for its product candidate. In the event the product is approved, sales will grow as the Corporation provides evidence of opioid reduction.
PANAG – Tetra Bio-Pharma Updates:
PPP003:
Panag expects to launch its Combined Phase 1&2 program in painful dry eye in Q4 2019. Panag will evaluate the safety and tolerability of the product candidate HU308, a non-controlled cannabinoid-derived medicine which is expected to provide significant pain relief. Non-controlled signifies that the product is not considered to be a narcotic. We have initiated discussions with potential commercialization partners for this product. In addition, Panag in partnership with a veterinary ophthalmologist will conduct a proof-of-concept Phase 2 clinical trial in domestic dogs with HU308. “What is particularly noteworthy is that the study will involve domestic pets and not laboratory animals with a goal of providing pet owners with an alternative ophthalmic pain medication,” stated Dr. Chamberland. As previously announced, Tetra intends to create a Business Unit in the lucrative veterinary health market.
PPP009:
Panag expects to launch its Combined Phase 1&2 program in uveitis, an inflammatory eye condition, by Q1 2020. Panag will evaluate the safety and tolerability of a cannabinoid formulation for the management of this condition. Patients with uveitis are largely dissatisfied with the current standard of care and represent a population with a huge unmet medical need.
Chronic Pain Product Candidates:
Panag is developing a medical food therapy, along with intellectual property, for the treatment of interstitial cystitis. The non-controlled status of the medicinal ingredient will allow Tetra to target global markets. Tetra plans to begin commercializing some of these products in 2020 while Panag continues the development of a prescription drug product for both humans and pets.
Dermatology Rx and OTC Product Candidates:
After completion of the Panag Pharma acquisition in May 2019, Tetra has accelerated its development of PPP004, a topical formulation of THC and CBD targeting the general neuropathic pain drug market. On the clinical side, Panag and Tetra have developed a protocol targeting pain and inflammation in patients suffering from general neuropathic pain and have engaged clinical sites capable of running the trial. In parallel, Tetra has made significant progress in manufacturing PPP004, including securing supplies of GMP active pharmaceutical ingredients (APIs; synthetic THC and CBD), sourcing and purchasing scalable manufacturing equipment at the Company’s manufacturing partner in Moncton, New Brunswick; and engaging formulation experts to refine the formulation of PPP004 to underpin the development of a robust line of topical products that will meet the rigorous quality requirements of pharmaceutical products. These clinical and quality/manufacturing activities have allowed Tetra to develop documentation in preparation for regulatory filing, which is projected to occur in late 2019.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
About Panag Pharma
Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safe, non-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the world’s leading researchers and clinicians in pain treatment and management. They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag’s current pipeline of pain relief products include formulations for the topical application to the skin, the eye and other mucous membranes. Recently approved by Health Canada and currently undergoing clinical trials, Panag Pharma’s Topical A OTC provides a new approach to the treatment of chronic pain and inflammation.
- Published in News Home, Tetra Bio Pharma
New Hemp Energy Drink to be offered to consumers in cannabis accessory stores, vapes stores, and kiosks in Canada and the US
Momentum Public Relations
Press Release: June 18, 2019
Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed an exclusive agreement with Spyder Cannabis Inc. (TSX VENTURE: SPDR) (“Spyder”) to distribute the three flavors of its Hemp Energy Drink in cannabis accessory stores and vapes stores in Canada and the US. The drink is expected to be available to consumers in Spyder’s retail stores located in Scarborough, Woodbridge, Burlington, and shortly at the Niagara Falls and Pickering locations, which are expected to be opened early this summer. A launch event will be held during the Canada Day long weekend at the Niagara Falls location situated at 6474 Lundys Lane.
“We are very excited to be adding the Hemp Energy Drink to our portfolio of premium brands that will be available to our growing clientele,” stated Daniel Pelchovitz, CEO and President of Spyder. “This new offering will please our customers who are always seeking unique and distinctive quality products in this emerging industry.”
“This exclusive agreement allows us to take another step in implementing our distribution strategy and achieving our goal of making our Hemp Energy Drink accessible to all consumers “ said Richard Giguère, CEO of Tetra Natural Health “Consumers appreciate the qualities of the Hemp Energy Drink (HED) including the fact that it contains more natural ingredients than other energy drinks, and is the first energy drink made with hemp available in the country” adds Derek Theriault, National Sales Director of Tetra Natural Health.
About Tetra Natural Health:
Tetra Natural Health Inc. is a subsidiary of Tetra Bio-Pharma Inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada. For more information, visit: www.tetranaturalhealth.com
About Spyder Cannabis Inc.
Founded in 2014 Spyder is an established chain of three high-end vape stores in Ontario, with stores located in Woodbridge, Scarborough and Burlington. The Spyder brand is defined by its high-quality proprietary line of e-juice, liquids and exclusive retail deals, dispensed in uniquely designed stores creating the optimal customer experience. Spyder is building off this leading retail, distribution and branding eCig and vapes company and is pursuing expansion into the legal cannabis market. Spyder has developed a scalable retail model with an aggressive expansion plan to create a significant retail footprint with targeted and disciplined retail distribution strategy focusing on Canadian locations in high traffic peripheral areas.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
More information at: www.tetrabiopharma.com
For more information, please contact:
Tetra Natural Health
Richard Giguère, CEO
Tel.: (348) 899-7575 ext. 210
rgiguere@tetranaturalhealth.com
Spyder Cannabis Inc.
Dan Pelchovitz, President and CEO
Tel: (905) 265-8273
dan@spydervapes.com
- Published in Cannabis, Marijuana, Medical Marijuana, News Home
Maurizio Napoli Joins Crystal Lake Mining’s Team as Vice-President of Exploration
Momentum Public Relations
Press Release: June 18, 2019
Crystal Lake Mining Corporation (TSXV: CLM) (OTC Pink: SIOCF) (FSE: SOG-FF) (“Crystal Lake” or the “Company“) is pleased to announce the appointment of Maurizio “Mars” Napoli as VP Exploration, effective immediately.
Mars Napoli is an accomplished professional geologist with over 33 years of experience in the mineral exploration business. He began his career studying gold mineralization in Northern Ontario with the Ministry of Northern Development and Mines. Subsequently he worked for 30 years with Inco Ltd. and Vale Canada in the Thompson and Sudbury nickel camps and with their North American and Global Exploration groups exploring for Archean greenstone gold, magmatic-hosted nickel-copper, uranium and porphyry-style copper systems.
“We searched hard for the right candidate and we’re thrilled to have Mars join our team as VP Exploration,” stated Richard Savage, Crystal Lake President and CEO. “His experience with high-grade gold systems and a broad array of other deposit types will help drive our success this summer with the Newmont Lake Project in the Eskay Camp.”
Napoli is an experienced exploration program manager from grassroots and brownfield exploration through to discovery and resource definition. He managed large exploration programs for Vale Canada and Sudbury Basin groups. The exploration teams Mars worked with enjoyed large world-class economic discoveries in Thompson, Sudbury and South America.
“Crystal Lake’s project has so many exciting components to it with multiple discovery opportunities given the historic data I’ve analyzed and the work we’ve already carried out,” stated Napoli. “I’m excited to be part of what I consider to be an exceptional team in the right area at the right time. With state-of-the-art exploration tools at our disposal, and such a prospective large land package, Crystal Lake has quickly become a key player in the Eskay district and the broader Golden Triangle.”
Napoli, who graduated with honours in 1983 and received his Master’s degree from Laurentian University in 2003, is a registered Professional Geologist with the Association of Professional Geologists of Ontario.
About Crystal Lake Mining
Crystal Lake Mining is a Canadian-based junior exploration company focused on building shareholder value through high-grade discovery opportunities in British Columbia and Ontario. The Company has an option to earn a 100% interest in the Newmont Lake Project, one of the largest land packages among juniors in the broader Eskay region in the heart of Northwest B.C.’s Golden Triangle.
On Behalf of the Board of Directors,
CRYSTAL LAKE MINING CORP.
“Richard Savage”
President & CEO
Email: info@crystallakemining.com
For further information please contact:
MarketSmart Communications
Tel: +1 (604) 261-4466
Toll Free: +1 (877) 261-4466
Email: info@marketsmart.ca
Momentum Public Relations
Tel: +1 (514) 815-7473
Email: mark@momentumpr.com
Maurizio Napoli Joins Crystal Lake Mining’s Team as Vice-President of Exploration
Cannot view this image? Visit:
https://orders.newsfilecorp.com/files/6406/45678_maurizio.jpg
- Published in Crystal Lake Mining, Mining, News Home
Vanstar announces AGM results and the election of directors
Momentum Public Relations
Press Release: June 17, 2019
Vanstar Mining Resources Inc. announces that the seven candidates designated in the management proxy circular dated May 10, 2019 were elected to the Corporation’s Board of Directors during the shareholders’ annual meeting held in Longueuil on June 13, 2019.
The shareholders were represented in person or by proxy by 20,241,497 class A shares, or 42.65% of the 47,463,328 outstanding class A shares.
Voting results are presented below:
- Percentage of votes in favour of the nomination of the directors proposed varies from 82.78% to 100%. Thus, MM. Guy Morissette, Pascal Germain, Eric Beauchêsne, Eric Gervais, Gary Claytens, Jonathan Hamel and Martin Richard were re-elected directors of the company.
- The appointment of Brunet Roy Dubé, CPA, as Independent auditor for the Company was approved at 100%.
- The amendment of the stock option plan was approved at 88.77%.
Certain information contained in the press release are subject to receipt of all regulatory
approvals. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
For more information on Vanstar, visit our website at www.vanstarmining.com.
Source : Guy Morissette
President and CEO
819-763-5096
gmvanstar@gmail.com
- Published in Mining, News Home, Vanstar Mining
Tetra Bio-Pharma Announces PPP003 Program Update Following Type B Meeting With U.S. FDA
Momentum Public Relations
Press Release: June 17, 2019
Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-derived drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF) today announced that it conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its non-controlled cannabinoid drug product PPP003 slated for the treatment of painful dry eye. The purpose of the meeting was to obtain confirmation of the Phase II clinical study design and the quality and toxicology requirements for initiating this trial in patients in the USA.
The FDA confirmed the proposed quality information requirements for initiating the Phase II trial in patients. This included a container closure system, stability plans, drug substance and drug product specifications. The FDA also provided feedback on the GLP toxicology requirements to initiate the Phase II trial.
The FDA reviewed the proposed Phase II clinical study and agreed that it was acceptable to evaluate the safety and efficacy of PPP003 Ophthalmic Solution for the treatment of the signs and symptoms of painful dry eye. The FDA also provided guidance on acceptable primary and secondary endpoints.
“This program is a corporate priority for Tetra and Panag since there is a significant unmet medical need for ophthalmic drugs,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “The choice of the non-controlled cannabinoid was important as the Company is aiming for global market penetration. We are extremely pleased that the U.S. FDA validated our ophthalmic research program. This program confirms that our research and development team is on the right track. With this confirmation and guidance, Tetra can now complete the execution of the clinical program for PPP003 intended to target the same important dry eye market as Xiidra™ which was recently acquired by Novartis from Takeda for $3.4Bn with $1.6Bn in potential milestone payments.”
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabinoids and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in News Home, Tetra Bio Pharma
Sirona Biochem Announces TFC-1067 Skin Lightening Patent Granted in USA
Momentum Public Relations
Press Release: June 17, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is pleased to announce that the patent for TFC-1067 entitled “Gem Difluorocompounds as Depigmenting or Lightening Agents” was granted in the USA, as expected, and will be published in the official database in the coming month. To date, the TFC1067 skin lightening patent has been granted in Germany, France, United Kingdom and now the US. Further TFC-1067 patent applications are in the patent pending status in multiple other countries while they go through the normal approval process.
TFC-1067, Sirona’s proprietary skin lightening compound, is superior to current actives on the market, safe and free of hydroquinone. The compound has undergone extensive testing, both preclinical and clinical, including a double blinded study for dyschromia in the US. Clinical results were received in late February 2019 and showed the compound to be superior to hydroquinone in the treatment of dyschromia with no adverse side effects. Sirona is currently in advanced negotiations in North America and Asia in regards to licensing rights for TFC-1067.
“This patent grant in one of the largest skin care markets is another important milestone for TFC-1067. The patent application was without concern to our potential partners as determined by their IP lawyers however it is an important and exciting milestone to reach,” said Dr. Howard Verrico, CEO of Sirona Biochem. “This will allow our potential US partners’ absolute IP certainty to move forward with their product marketing plans.”
The global skin lightening market is expected to reach $23 Billion USD by 2022[1].
About Sirona Biochem Corp
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Jonathan Williams
Managing Director
Momentum PR
Phone: 1.450.332.6939
Email: jwilliams@momentumpr.com
[1] https://www.factmr.com/report/309/skin-lightening-products-market
- Published in Life Sciences, News Home, Sirona Biochem
Sirona Biochem Appoints Chinese Lawyer Jason Tian to its Board of Directors
Momentum Public Relations
Press Release: June 12, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) announces that Mr. Jason Tian will be joining its Board of Directors. Jason Tian is a Senior Partner at Landing Law offices based in Shanghai, China. Jason has been working with Sirona since 2018 representing the Company at strategic partnering meetings in China and France.
Jason Tian has been providing legal services to international clients since 2007 and has worked in top firms in China such as Beijing Zhonglun, Beijing Zhongyin, Beijing Dacheng and is now a Senior Partner of Shanghai Landing Law Offices. He also worked as senior legal translator in UK-based firm, Clifford Chance LLP, before starting his legal career.
Shanghai Landing Law Offices is a full-service law firm with headquarters in Shanghai, China. Lawyers at Landing provide full-service to clients in industries such as healthcare and pharmaceuticals as well as consumer retail in China. Landing has several domestic branches and overseas branches in the United States, India, Singapore, Indonesia, Bangladesh, Philippines and Cambodia.
“Sirona’s management team has developed an excellent working relationship with Jason. His legal knowledge and extensive network in the Chinese business community are proving to be tremendous assets to Sirona”, reports Sirona Biochem’s CEO Dr Howard Verrico.
The company also announces Casper Bych has resigned from Sirona’s Board of Directors.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law. The appointment of Jason Tian to the BOD is subject to exchange approval.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2019/12/c2009.html
Contact:
regarding this press release, please contact: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com
- Published in Business, Life Sciences, News Home, Sirona Biochem, Technology
Crystal Lake Mining’s Discovery Team Outlines Chachi Corridor Copper-Gold Target Area at Newmont Lake Project
Momentum Public Relations
Press Release: June 12, 2019
Crystal Lake Mining Corporation (TSXV: CLM) (OTC PINK: SIOCF) (FSE: SOG-FF) (“Crystal Lake” or the “Company“) is pleased to announce that a large copper-gold porphyry target area, with high-grade gold potential, has been outlined on the eastern side of the Company’s Newmont Lake Project in Northwest B.C.’s Eskay Camp.
The northeast trending Chachi Corridor along the McLymont fault system has a current strike length of greater than 8 km by 3 km wide as defined by an extensive review of historic data including rocks, soils and geophysics. The entire corridor, which features astonishing glacial retreat, is notably underexplored and will be one of several primary areas of focus for the 2019 summer exploration program, now underway.
Location
The Chachi Corridor begins approximately 6 km northeast of the historic Northwest Gold zone (“NW Zone”) and 20 km northeast of Crystal Lake’s recent drilling discovery at Burgundy Ridge (March 7, 2019, news release), underscoring both the scale and potential of the entire 430 sq. km Newmont Lake Project located in the heart of the Golden Triangle.
A broad and flat glacial valley ranging in elevation from 500 to 700 meters begins at the northeast tip of the Chachi Corridor and continues in a straight direction northeastward for approximately 20 km to the Galore Creek access road west of the Bob Quinn Airstrip. Additionally, infrastructure and access to the southern portion of the Newmont Lake Project have recently been upgraded with the completion and power production of AltaGas’ Northwest Hydroelectric facilities, including the 66-MW McLymont Creek power plant which sits at the southern tip of Crystal Lake’s land package 15 km northwest of Nickel Mountain.
Location of Crystal Lake Mining’s Newmont Lake Project in the prolific Eskay Mining Camp of Northwest BC, Canada
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6406/45530_7a9c6af784f39848_001full.jpg
Glacial Retreat Opens Corridor
Based on cross referencing old and new satellite imagery and orthographic photos, glacial retreat of approximately 2 to 4 kilometers has occurred within the Chachi Corridor since parts of it were last explored with “boots on the ground” in 2008. Widespread surface alteration, intrusive bodies and other geological features consistent with large-scale porphyry copper-gold and associated shear vein gold and/or carbonate replacement gold systems are apparent in the geochemical data compilation. This plus the newly exposed prospective ground makes the entire Chachi Corridor a high-priority target.
Satellite image showing the extent of glacial retreat along Chachi Corridor from 2002 to 2018
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6406/45530_7a9c6af784f39848_002full.jpg
Chachi Corridor Additional Highlights:
- Three separate intense geochemical anomalies (copper, gold and silver), vectoring into vast unexplored and highly altered terrain, covering an area greater than 8 km by 3 km;
- An approximate 3 km gossanous zone is adjacent to a cluster of dioritic and syenitic intrusions (typical intrusion types to host large porphyry systems and mineral occurrences in this region), all spatially associated with the McLymont Fault system of extensional tectonics in the region;
- A radiometric age-dating study at the University of British Columbia (“UBC”) concluded late Triassic ages of 203.1 ± 2.0 Ma to 214.1 ± 2.0 Ma on two sampled intrusions to date in the Chachi Corridor, which puts a copper-gold porphyry system in the Corridor remarkably similar in age to the Newmont/Teck Galore Creek/Copper Canyon deposits approximately 40 km to the northwest (Assessment Report #30749, B.C. Geological Survey);
- Limited historic rock sampling (late 1980’s) over a strike length of 1 km from an interpreted epithermal area on the eastern side of the Chachi Corridor returned values ranging from anomalous to 14.2 g/t Au, with 8 of the 28 samples grading >8 g/t Au (Assessment Report #18450).
Richard Savage, President and CEO of Crystal Lake, commented: “The right people, the right area, the right time – we’ve assembled an amazing team that’s planning an expansive initial exploration program that will be systematic and discovery-driven, applying state-of-the-art exploration technologies.”
Chachi Phase 1 Exploration Program
A team of approximately 20 people at any given time will be exploring and validating the Chachi Corridor. A Phase 1 program consisting of extensive prospecting, lithological and alteration mapping, airborne and ground geophysics, and geochemical and alteration vectoring using the latest in-field mobile hyperspectral and X-ray Fluorescence (“XRF”) technology should quickly define priority targets for drill testing this summer.
Corporate Update
Crystal Lake Mining is currently in the process of rebranding and building its new investor website, corporate presentation, geological and investor maps and more. To find out more about the company and to be notified when these items are available, email info@crystallakemining.com or sign-up on our current website to receive all email alerts.
Qualified Person
The technical information in this news release has been reviewed and approved by Mr. Abdul Razique, PhD., P.Geo., a Qualified Person responsible for the scientific and technical information in this news release under National Instrument 43-101 standards.
About Crystal Lake Mining
Crystal Lake Mining is a Canadian-based junior exploration company focused on building shareholder value through high-grade discovery opportunities in British Columbia and Ontario. The Company has an option to earn a 100% interest in the Newmont Lake Project, one of the largest land packages among juniors in the broader Eskay region in the heart of Northwest B.C.’s Golden Triangle.
This news release may contain certain “forward looking statements”. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Any forward-looking statement speaks only as of the date of this news release and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
On Behalf of the Board of Directors,
CRYSTAL LAKE MINING CORP.
“Richard Savage”
President & CEO
Email: info@crystallakemining.com
Website: www.crystallakeminingcorp.com
For further information please contact:
Momentum Public Relations
Tel: +1 (514) 815-7473
Email: mark@momentumpr.com
- Published in Crystal Lake Mining, Mining, News Home